

Title (en)  
ANTIBODY AND/OR CHEMOKINE CONSTRUCTS WHICH BIND TO A CHEMOKINE RECEPTOR AND THEIR USE IN IMMUNOLOGICAL DISORDERS

Title (de)  
ANTIKÖRPER- UND/ODER CHEMOKINKONSTRUKTE DIE AN EINEN CHEMOKINREZEPTOR BINDEN UND DEREN VERWENDUNG IN IMMUNOLOGISCHEN ERKRANKUNGEN

Title (fr)  
CONSTRUCTIONS D'ANTICORPS ET/OU DE CHIMIOKINE QUI SE LIE A UN RECEPTEUR CHIMIOKINE ET LEUR UTILISATION CONTRE DES TROUBLES IMMUNOLOGIQUES

Publication  
**EP 1317284 A2 20030611 (EN)**

Application  
**EP 01980364 A 20010910**

Priority

- EP 01980364 A 20010910
- EP 0110433 W 20010910
- EP 00119694 A 20000908
- US 94800401 A 20010905

Abstract (en)  
[origin: WO0220615A2] The present invention relates to the use of an antibody and/or chemokine construct which binds to a chemokine receptor for the preparation of a pharmaceutical composition for the elimination of cells which are latently infected with a primate immunodeficiency virus. In addition, the present invention provides for the use of an antibody and/or chemokine construct which binds to a chemokine receptor for the preparation of a pharmaceutical composition of the treatment, prevention and/or alleviation of inflammatory renal diseases, inflammatory bowel diseases, multiple sclerosis, skin diseases, diabetes or transplant rejection. Furthermore, the invention relates to antibody constructs and/or chemokine constructs wherein said antibody construct comprises a binding site of chemokine receptor 5 and a binding site for CD3 and wherein said chemokine construct comprises RANTES and a toxin. The invention also describes polynucleotides encoding said antibody- or chemokine constructs, and vectors and hosts comprising said nucleic acid molecules. Additionally, the present invention relates to compositions comprising said antibody constructs, chemokine constructs, polynucleotides, vectors and/or hosts. Preferably said composition is a pharmaceutical composition. Described is also the use of antibody constructs, the chemokine constructs, the polynucleotides, the hosts and/or the vectors of the preparation of a pharmaceutical composition and methods for treating, preventing and/or alleviating an immunological disorder or for eliminating latently infected cells, wherein said cells are infected with a primate immunodeficiency virus, like HIV-1. Furthermore, the invention provides for a kit comprising the compounds of the invention.

IPC 1-7  
**A61K 39/395**; **A61K 38/19**; **A61K 47/48**; **C12N 15/12**; **C12N 15/13**; **C12N 15/62**; **C12N 15/79**; **C07K 16/28**; **C07K 19/00**; **A61K 31/7088**; **A61P 17/00**; **A61P 19/00**; **A61P 31/18**; **A61P 37/06**

IPC 8 full level  
**A61K 31/7088** (2006.01); **A61K 35/76** (2006.01); **A61K 38/00** (2006.01); **A61K 38/19** (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61K 45/06** (2006.01); **A61K 47/48** (2006.01); **A61P 1/00** (2006.01); **A61P 3/10** (2006.01); **A61P 13/12** (2006.01); **A61P 17/00** (2006.01); **A61P 17/06** (2006.01); **A61K 48/00** (2006.01); **A61P 19/00** (2006.01); **A61P 19/02** (2006.01); **A61P 25/00** (2006.01); **A61P 29/00** (2006.01); **A61P 31/18** (2006.01); **A61P 37/02** (2006.01); **A61P 37/06** (2006.01); **A61P 37/08** (2006.01); **C07K 14/52** (2006.01); **C07K 14/715** (2006.01); **C07K 16/28** (2006.01); **C07K 19/00** (2006.01); **C12N 1/15** (2006.01); **C12N 1/19** (2006.01); **C12N 1/21** (2006.01); **C12N 5/10** (2006.01); **C12N 15/09** (2006.01); **C12N 15/12** (2006.01); **C12N 15/13** (2006.01); **C12N 15/62** (2006.01); **C12N 15/79** (2006.01); **C12P 21/02** (2006.01); **C12P 21/08** (2006.01); **A61K 39/00** (2006.01)

IPC 8 main group level  
**C07K** (2006.01)

CPC (source: EP)  
**A61P 1/00** (2018.01); **A61P 3/10** (2018.01); **A61P 13/12** (2018.01); **A61P 17/00** (2018.01); **A61P 17/06** (2018.01); **A61P 19/00** (2018.01); **A61P 19/02** (2018.01); **A61P 25/00** (2018.01); **A61P 29/00** (2018.01); **A61P 31/18** (2018.01); **A61P 37/02** (2018.01); **A61P 37/06** (2018.01); **A61P 37/08** (2018.01); **C07K 14/523** (2013.01); **C07K 16/2809** (2013.01); **C07K 16/2866** (2013.01); **A61K 38/00** (2013.01); **A61K 48/00** (2013.01); **A61K 2039/505** (2013.01); **C07K 2317/34** (2013.01); **C07K 2317/77** (2013.01); **C07K 2319/00** (2013.01)

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)  
**WO 0220615 A2 20020314**; **WO 0220615 A3 20020725**; AU 1222502 A 20020322; CA 2421842 A1 20020314; EP 1317284 A2 20030611; HU P0300942 A2 20030929; JP 2004508036 A 20040318; NO 20031070 D0 20030307; NO 20031070 L 20030506; PL 366062 A1 20050124; RU 2252786 C2 20050527; ZA 200301890 B 20040316

DOCDB simple family (application)  
**EP 0110433 W 20010910**; AU 1222502 A 20010910; CA 2421842 A 20010910; EP 01980364 A 20010910; HU P0300942 A 20010910; JP 2002525234 A 20010910; NO 20031070 A 20030307; PL 36606201 A 20010910; RU 2003108885 A 20010910; ZA 200301890 A 20030307